

| | | |
|--|--|---|
| Statement of Deficiencies | (X1) Provider/Supplier/CLIA Identification Number 03D2160987 | (X3) Date Survey Completed 08/04/2025 |
| Name of Provider or Supplier Honorhealth Mesa Emergency Center | Street Address, City, State 5750 E Baseline Rd, Mesa, AZ | |
| For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency. | | |

| (X4) ID Prefix Tag | Summary Statement of Deficiencies |
|---------------------------|--|
| D0000 | Based on a proficiency testing desk review survey performed on August 4, 2025, the laboratory was found to be out of compliance based on the following CONDITION LEVEL DEFICIENCIES : D2016 - 42 C.F.R. 493.803 Condition: Successful Participation D6000 - 42 C.F.R. 493.1403 Condition: Laboratory Director, moderate complexity |
| D2016 | <p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on review of the Certification and Survey Enhanced Reporting (CASPER) 155 report and College of American Pathologists (CAP) proficiency testing records, the laboratory failed to successfully participate in two of three consecutive testing events</p> |

| | |
|---------------------|--|
| | <p>in the subspecialty of Endocrinology and the regulated analyte, HCG, in 2025 resulting in an initial unsuccessful performance. Refer to D2107 and D2108. 1. The laboratory's PT performance was unsatisfactory for the first event of 2025 as indicated below: - Endocrinology - 0% -HCG - 0% 2. The laboratory's PT performance was unsatisfactory for the second event of 2025 as indicated below: - Endocrinology - 0% - HCG - 0%</p> |
| <p>D2107</p> | <p>ENDOCRINOLOGY CFR(s): 493.843(f)</p> <p>(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.</p> <p>This STANDARD is not met as evidenced by: Based on review of the CASPER 155 report and College of American Pathologists (CAP) PT records from 2025, the laboratory failed to achieve satisfactory performance (80%) for two of three consecutive testing events for the regulated analyte, HCG. Findings include: 1. A review of the CASPER 155 report revealed the following unsatisfactory scores: 2025 event 1, HCG 0% 2025 event 2, HCG 0% 2. A review of the proficiency testing scores from CAP (2025) confirmed the above findings.</p> |
| <p>D2108</p> | <p>ENDOCRINOLOGY CFR(s): 493.843(g)</p> <p>(g) Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.</p> <p>This STANDARD is not met as evidenced by: Based on review of the CASPER 155 report and College of American Pathologists (CAP) PT records from 2025, the laboratory failed to achieve satisfactory performance (80%) for two of three consecutive testing events in the subspecialty of Endocrinology. Findings include: 1. A review of the CASPER 155 report revealed the following unsatisfactory scores: 2025 event 1, subspecialty of Endocrinology 0% 2025 event 2, subspecialty of Endocrinology 0% 2. A review of the proficiency testing scores from CAP (2025) confirmed the above findings.</p> |
| <p>D6000</p> | <p>MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403</p> <p>The laboratory must have a director who meets the qualification requirements of 493.1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart.</p> <p>This CONDITION is not met as evidenced by: Based on a proficiency testing desk review of the CASPER-0155 Individual</p> |

Laboratory Report and College of American Pathologists (CAP) 2025 records, the laboratory director failed to provide overall management and direction of the laboratory services. Refer to D6016.

D6016

LABORATORY DIRECTOR RESPONSIBILITIES

CFR(s): 493.1407(e)(4)(i)

(e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part;

This STANDARD is not met as evidenced by:

Based on a proficiency testing desk review of the CASPER-0155 and College of American Pathologists (CAP) 2025-1 and 2025-2, evaluation reports, the laboratory director failed to ensure successful participation in an HHS approved proficiency testing program.